XML 13 R2.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Consolidated Balance Sheets - USD ($)
Mar. 31, 2025
Jun. 30, 2024
Current assets    
Cash and cash equivalents $ 2,807,112 $ 6,304,098
Accounts receivable, net 510,963 429,704
Inventories, net 683,488 777,537
Research and development tax incentive receivable 520,312 525,332
Other current assets 585,456 497,572
Total current assets 5,107,331 8,534,243
Property and equipment, net 546,458 565,850
Operating lease right-of-use assets 126,798 306,744
Intangibles, net 3,803,940 4,372,026
Total assets 9,584,527 13,778,863
Current liabilities    
Accounts payable and accrued expenses 1,330,556 1,704,568
Current portion of operating lease liabilities 151,322 274,834
Current portion of deferred grant income 2,278,681 2,486,668
Current employee benefit liabilities 447,670 469,381
Current portion of notes payable 356,156 515,282
Total current liabilities 4,564,385 5,450,733
Employee benefit liabilities, less current portion 72,672 63,615
Operating lease liabilities, less current portion 3,704 81,324
Total liabilities 4,640,761 5,595,672
Commitments and contingencies (Note 10)
Shareholders’ equity    
Common stock, $0.01 par value, 100,000,000 shares authorized, 6,794,395 and 3,456,000 shares issued and outstanding as of March 31, 2025 and June 30, 2024, respectively 67,941 34,557
Treasury stock, at cost, 116 shares as of March 31, 2025 and June 30, 2024, respectively (1) (1)
Additional paid-in capital 65,012,004 60,971,740
Accumulated deficit (59,442,961) (51,964,332)
Accumulated other comprehensive loss (523,417) (712,614)
Total consolidated Intelligent Bio Solutions Inc. equity 5,113,566 8,329,350
Non-controlling interest (169,800) (146,159)
Total shareholders’ equity 4,943,766 8,183,191
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY $ 9,584,527 $ 13,778,863